Novo Nordisk (NVO)
(Delayed Data from NYSE)
$134.89 USD
-2.68 (-1.95%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $135.19 +0.30 (0.22%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Novo Nordisk (NVO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$146.86 | $166.00 | $84.00 | 6.75% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Novo Nordisk comes to $146.86. The forecasts range from a low of $84.00 to a high of $166.00. The average price target represents an increase of 6.75% from the last closing price of $137.57.
Analyst Price Targets (7 )
Broker Rating
Novo Nordisk currently has an average brokerage recommendation (ABR) of 1.58 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.58 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 69.23% and 7.69% of all recommendations. A month ago, Strong Buy made up 69.23%, while Buy represented 7.69%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NVO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 10 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.58 | 1.58 | 1.58 | 1.54 | 1.54 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
7/11/2024 | Cowen & Co. | Michael Nedelcovych | Strong Buy | Strong Buy |
6/17/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
6/10/2024 | Argus Research Corp. | John M Eade | Strong Buy | Strong Buy |
5/30/2024 | Goldman Sachs | James Quigley | Not Available | Strong Buy |
1/16/2024 | UBS | Jo Walton | Not Available | Hold |
11/12/2023 | Guggenheim Securities | Seamus Fernandez | Not Available | Strong Buy |
11/1/2023 | Exane BNP Paribas | Richard Parkes | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.58 |
ABR (Last week) | 1.58 |
# of Recs in ABR | 13 |
Average Target Price | $146.86 |
LT Growth Rate | 29.40% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 61 of 253 |
Current Quarter EPS Est: | 0.91 |